TNF-α is a central risk factor in the pathogenesis of these diseases, and treatment of rheumatoid arthritis with the anti-TNF-α antibody infliximab improves the number and functional properties of EPCs11,24, indicating a close relationship between TNF-α and EPC dysfunction. Here, TNF is linked to rheumatoid arthritis.